David Dai
Stock Analyst at UBS
(0.29)
# 4,022
Out of 4,818 analysts
20
Total ratings
16.67%
Success rate
-32.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVL Nuvalent | Upgrades: Buy | $100 | $72.70 | +37.55% | 2 | Mar 14, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $27 → $14 | $6.38 | +119.61% | 2 | Mar 6, 2025 | |
| IMCR Immunocore Holdings | Initiates: Sell | $24 | $29.86 | -19.62% | 1 | Oct 24, 2024 | |
| BPMC Blueprint Medicines | Initiates: Neutral | $88 | $85.93 | +2.41% | 1 | Oct 24, 2024 | |
| CATX Perspective Therapeutics | Initiates: Buy | $20 | $2.34 | +754.70% | 1 | Oct 24, 2024 | |
| NRIX Nurix Therapeutics | Initiates: Buy | $35 | $11.68 | +199.66% | 1 | Oct 24, 2024 | |
| MRUS Merus | Initiates: Buy | $72 | $41.90 | +71.84% | 1 | Oct 24, 2024 | |
| JANX Janux Therapeutics | Initiates: Buy | $69 | $31.66 | +117.94% | 1 | Oct 24, 2024 | |
| IDYA IDEAYA Biosciences | Initiates: Buy | $50 | $18.84 | +165.46% | 1 | Oct 24, 2024 | |
| IOVA Iovance Biotherapeutics | Initiates: Buy | $17 | $3.19 | +432.92% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $8.41 | +256.93% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $20.73 | +189.44% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $13.01 | +184.40% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $0.60 | +4,555.80% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $12.16 | +228.95% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $1.71 | +2,239.18% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $2.18 | +2,198.85% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $33.56 | +54.95% | 1 | Mar 17, 2020 |
Nuvalent
Mar 14, 2025
Upgrades: Buy
Price Target: $100
Current: $72.70
Upside: +37.55%
Kura Oncology
Mar 6, 2025
Maintains: Buy
Price Target: $27 → $14
Current: $6.38
Upside: +119.61%
Immunocore Holdings
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $29.86
Upside: -19.62%
Blueprint Medicines
Oct 24, 2024
Initiates: Neutral
Price Target: $88
Current: $85.93
Upside: +2.41%
Perspective Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $20
Current: $2.34
Upside: +754.70%
Nurix Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $35
Current: $11.68
Upside: +199.66%
Merus
Oct 24, 2024
Initiates: Buy
Price Target: $72
Current: $41.90
Upside: +71.84%
Janux Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $69
Current: $31.66
Upside: +117.94%
IDEAYA Biosciences
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $18.84
Upside: +165.46%
Iovance Biotherapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $17
Current: $3.19
Upside: +432.92%
Oct 24, 2024
Initiates: Buy
Price Target: $30
Current: $8.41
Upside: +256.93%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $20.73
Upside: +189.44%
Oct 24, 2024
Initiates: Buy
Price Target: $37
Current: $13.01
Upside: +184.40%
Mar 31, 2022
Initiates: Outperform
Price Target: $28
Current: $0.60
Upside: +4,555.80%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $12.16
Upside: +228.95%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $1.71
Upside: +2,239.18%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $2.18
Upside: +2,198.85%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $33.56
Upside: +54.95%